Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

Xenon Pharmaceuticals Inc. ( XENE ) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDT Company Participants Colleen Alabiso - Senior Vice President of Corporate Affairs Ian Mortimer - President, CEO & Director Christopher Kenney - Chief Medical Officer Darren Cline - Chief Commercial Officer Thomas Kelly - Chief Financial Officer Conference Call Participants Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Matthew Barcus - Jefferies LLC, Research Division Brian Skorney - Robert W. Baird & Co. Incorporated, Research Division Joseph Thome - TD Cowen, Research Division Brian Abrahams - RBC Capital Markets, Research Division Myles Minter - William Blair & Company L.L.C., Research Division David Hoang - Deutsche Bank AG, Research Division Benjamin Burnett - Wells Fargo Securities, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for standing by. My name is Angela, and I will be your conference operator today. At this time, I would like to welcome everyone to the Second Quarter 2026 Xenon Pharmaceuticals, Inc. Earnings Conference Call. I'd like to remind everyone that this call is being recorded.

I would now like to turn the call over to Ms. Colleen Alabiso, Senior Vice President of Corporate Affairs at Xenon Pharmaceuticals, Inc. You may begin. Colleen Alabiso Senior Vice President of Corporate Affairs Good afternoon. Thank you for joining us on our call and webcast to discuss Xenon's second quarter 2026 Financial and Operating Results. Joining me today are Ian Mortimer, President and Chief Executive Officer; Dr. Chris Kenney, Chief Medical Officer; Darren Cline, Chief Commercial Officer; and Tucker Kelly, Chief Financial Officer. After completing our prepared remarks today, we will open the call up for your questions. Please be advised that during this call, we will make a number of statements that are forward-looking, including statements regarding the timing of and potential results from clinical